The TEMPLE study is an ongoing investigator-initiated phase 1 and phase 2 study conducted at the Phase 1 Unit at Rigshospitalet. The project is a completely novel strategy for improving response rates to immune checkpoint inhibitors by applying an innovative thiopurine combination to increase the mutational burden, presence of neoepitopes and thus proportion of patients with incurable solid cancers that respond to treatment with immune checkpoint inhibitors.
Current status of the study
The TEMPLE study was initiated in September 2022 and currently 12 patients have been included in the study. RP2D has been determined and recruitment for phase 2 has begun.
Link to presented poster